The supply shortage or limited availability affects some of the EU Member States where the medicine is marketed, including Belgium, Denmark, France, Germany, Luxembourg and Sweden; in some Member States, English-labelled packs for certain doses will be available until the end of 2025.

The EHC joins the International Society on Thrombosis and Haemostasis (ISTH), European Association for Haemophilia and Allied Disorders (EAHAD), World Federation of Hemophilia (WFH), and other leading international organisations in issuing a statement and urgent call-to-action for a continued commitment to innovation and access in haemophilia care.

Haemophilia is often perceived as a condition that only affects men, and this outdated view continues to affect care, diagnosis, and understanding of the condition in women. To challenge this bias and raise awareness, the EHC is releasing two new resources on World Haemophilia Day 2025.

Building on the discussions and momentum from the latest EHC Round Table on Advancing Women’s Health, on World Health Day, the EHC releases a new position paper urging policymakers to address the unique challenges faced by women with bleeding disorders.

Several days ago, the EHC received a statement from Novo Nordisk concerning manufacturing issues related to NovoSeven, NovoEight, and Esperoct.

On 25 March 2025, the EHC held a Round Table discussion titled ‘Advancing Women’s Health – The Importance of Early Diagnosis for Women with Bleeding Disorders’ at the European Parliament in Brussels, hosted by MEP Stine Bosse.